CDV3抗体;CDV3 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P13055(CDV3 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

The CDV3 (Cell Division Variant 3) gene, also known as RDM16 or C15orf44. encodes a protein implicated in cell proliferation and oncogenic processes. Initially identified through differential expression analyses in cancer, CDV3 is overexpressed in various malignancies, including hepatocellular carcinoma, pancreatic cancer, and leukemia. Its molecular function remains partially characterized, but studies suggest it interacts with β-catenin and modulates Wnt/β-catenin signaling, a pathway critical for tumorigenesis. CDV3 may also influence ribosome biogenesis or RNA metabolism, given its structural homology to RNA-binding proteins.

CDV3 antibodies are tools developed to detect and study the protein's expression, localization, and functional roles. Polyclonal and monoclonal antibodies targeting specific epitopes of CDV3 have been generated for immunohistochemistry, Western blotting, and immunofluorescence. These reagents enable researchers to investigate CDV3's overexpression patterns in tumors, correlate its levels with clinical outcomes, and explore its potential as a diagnostic or prognostic biomarker. Recent studies also explore CDV3 antibodies in preclinical settings, assessing their utility in blocking oncogenic signaling or enabling targeted drug delivery. Despite progress, challenges remain in fully elucidating CDV3's mechanistic contributions to cancer and its therapeutic targetability, driving ongoing research using antibody-based approaches.